Instituto de Enfermedades Crónico-Degenerativas, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Phytomedicine. 2010 Jun;17(7):500-5. doi: 10.1016/j.phymed.2009.10.014. Epub 2009 Dec 3.
Insulin resistance, obesity, hypertension, and dyslipidemia are strongly associated with metabolic syndrome (MeSy), which is considered to be a reversible clinical stage before its evolution to coronary heart disease and diabetes. Currently, the antihypertensive and hypolipidemic properties of aqueous Hibiscus sabdariffa extracts (HSE) have been demonstrated in clinical trials and in vivo experiments. The aim of the present study was to evaluate the effects of a Hibiscus sabdariffa extract powder (HSEP) and a recognized preventive treatment (diet) on the lipid profiles of individuals with and without MeSy according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria. The protocol was a follow-up study carried out in a factorial, randomized design (T1=preventive treatment comprises Diet, T2=HSEP, T3=HSEP+preventive treatment (Diet) X MeSy, non-MeSy individuals). A total daily dose of 100 mg HSEP was orally administered in capsules for one month. The preventive treatment (diet) was selected according to NCEP-ATP III recommendations and adjusted individually. Total cholesterol, LDL-c, HDL-c, VLDL-c, triglycerides, glucose, urea, creatinine, AST, and ALT levels in the blood were determined in all individuals pre- and post-treatment. The MeSy patients treated with HSEP had significantly reduced glucose and total cholesterol levels, increased HDL-c levels, and an improved TAG/HDL-c ratio, a marker of insulin resistance (t-test p<0.05). Additionally, a triglyceride-lowering effect was observed in MeSy patients treated with HSEP plus diet, and in individuals without MeSy treated with HSEP. Significant differences in total cholesterol, HDL-c, and the TAG/HDL-c ratio were found when the means of absolute differences among treatments were compared (ANOVA p<0.02). Therefore, in addition to the well documented hypotensive effects of Hibiscus sabdariffa, we suggest the use of HSEP in individuals with dyslipidemia associated with MeSy.
胰岛素抵抗、肥胖、高血压和血脂异常与代谢综合征（MeSy）密切相关，代谢综合征被认为是向冠心病和糖尿病发展之前的可逆转临床阶段。目前，临床研究和体内实验已经证实了水提葫芦巴提取物（HSE）的降压和降血脂作用。本研究旨在评估根据国家胆固醇教育计划成人治疗专家组第三版（NCEP-ATP III）标准，Hibiscus sabdariffa 提取物粉末（HSEP）和公认的预防治疗（饮食）对伴有和不伴有 MeSy 的个体血脂谱的影响。该方案是一项随访研究，采用析因随机设计（T1=预防治疗包括饮食，T2=HSEP，T3=HSEP+预防治疗（饮食）×MeSy，非 MeSy 个体）。每天口服 100mg HSEP 胶囊，持续一个月。预防治疗（饮食）根据 NCEP-ATP III 建议选择，并根据个体进行调整。所有个体在治疗前后均检测血液中的总胆固醇、LDL-c、HDL-c、VLDL-c、甘油三酯、葡萄糖、尿素、肌酐、AST 和 ALT 水平。用 HSEP 治疗的 MeSy 患者的血糖和总胆固醇水平显著降低，HDL-c 水平升高，胰岛素抵抗标志物 TAG/HDL-c 比值改善（t 检验 p<0.05）。此外，HSEP 联合饮食治疗 MeSy 患者和 HSEP 治疗非 MeSy 患者均可降低甘油三酯水平。当比较各处理间绝对差值的均值时，发现总胆固醇、HDL-c 和 TAG/HDL-c 比值有显著差异（ANOVA p<0.02）。因此，除了葫芦巴具有已证实的降压作用外，我们还建议在伴有 MeSy 的血脂异常患者中使用 HSEP。
